About us · Deep tech
The team bringing bioinspired biointerfaces to patients
Tirecat Health is a deep-tech spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Spanish National Research Council (CSIC), founded in 2024 in Barcelona.
Our team
The people behind RESKIN
Materials science, clinical practice, manufacturing and regulatory affairs, working together to take RESKIN to the clinic.
Co-founders
Co-founder & CTO
Dr. Salvio Suárez-García
PhD in Materials Science (UAB, 2019, cum laude and Extraordinary Doctorate Award). Senior Researcher in the NANOSFUN group at ICN2 and inventor of the technology behind RESKIN. Research stays at the University of British Columbia, the Medical University of Vienna, LCC-CNRS Toulouse, Kiel University and the Waterloo Institute for Nanotechnology. Leads technology development, regulatory strategy and funding.
Co-founder & CSO
Prof. Daniel Ruiz-Molina
CSIC Professor and leader since 2005 of the NANOSFUN group at ICN2, where the bioinspired catechol chemistry behind RESKIN was developed. He has supervised more than 20 PhD theses and transferred several patented technologies to industry. In 2026 he led the candidacy that won the Duran Farell Award for Technological Innovation. Leads the scientific direction of Tirecat Health.
Team
Clinical Expert
Dr. Judit Ruiz Calbet, MD
Medical doctor. Leads the clinical strategy and the coordination of clinical studies. Our link with clinicians.
Product Developer
Dr. José D. Bolaños
Postdoctoral researcher at ICN2 (NANOSFUN). Leads synthesis scale-up, transfer to manufacturing and antimicrobial validation.
Regulatory & Business Development
Dr. Verónica Arévalo
“la Caixa” Foundation fellow: her Health Innovation Fellowship funds her incorporation into Tirecat Health. Leads the regulatory technical file, funding and partnerships.
Our story
From public research to a company
Born in NANOSFUN
More than ten years of research on bioinspired catechol chemistry at ICN2-CSIC.
Patent filed
WO2022258780A1, owned by ICN2 and CSIC, with national phases in 8 jurisdictions.
Tirecat Health is founded
Exclusive worldwide licence and selection by CaixaImpulse Innovation.
CSIC joins
ICN2, CSIC and Criteria Capital Risc are shareholders, alongside the founders.
Preclinical phase completed
Two porcine wound models, the full ISO 10993 safety programme and a first batch made by a certified manufacturer.
First patient (target)
First study of RESKIN in patients with diabetic foot ulcer.
Our purpose
Our mission: to develop, manufacture and distribute bioinspired adhesive membranes, biointerfaces that revolutionise regenerative medicine worldwide.
Clinical and research network
Built with clinicians from day one
We have interviewed 35 clinicians in chronic wounds, infectious diseases and surgery across Spain and Italy, and we work with leading hospitals and research centres to design our first clinical study and future indications.
Our development is supported by specialised regulatory, preclinical (GLP) and manufacturing (ISO 13485) partners.
Funding and recognition
Backed by competitive programmes
AGAUR Llavor and Innovadors grants and ICN2 seed and valorisation funds
Barcelona Activa – Best high-tech business project
Proof of Concept – Spanish Ministry of Science (NextGenerationEU)
CaixaImpulse Innovation – “la Caixa” Foundation
Transfiere – Deep Tech Start-ups Award
Selected for the “la Caixa” Biotech Investor Forum
Health Innovation Fellowships – “la Caixa” Foundation
Duran Farell Award for Technological Innovation (NANOSFUN group)
RESKIN (CI24-20039) is supported by the CaixaImpulse Innovation programme of the “la Caixa” Foundation, and Tirecat Health hosts a fellow of the Health Innovation Fellowships – “la Caixa” Foundation.
The content of this website reflects only the authors’ view. The “la Caixa” Foundation is not responsible for any use that may be made of the information it contains.
Join us
Grow with Tirecat Health
Internships
Master’s and final-year students who want to learn how a deep-tech company takes a medical device to the clinic.
Research collaborations
Groups and clinicians who want to work with us on new indications of our bioinspired platform.
